Gadoterate Meglumine
Brand Names: Dotarem, Clariscan
Methodology & AI Transparency ⓘ
Gadoterate Meglumine Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Gadoterate Meglumine Injection is a gadolinium-based contrast agent indicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associated tissues in adult and pediatric patients (including term neonates) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity.
- 2 Real-world patient consensus: Tracked across 22 patient dosage logs with a 93% satisfaction benchmark (RxCUI RXN-70436123-1767).
- 3 Typical cash cost range: Uninsured 30-day outlay compares $40.90 cash mean against $100.20 retail pharmacy pricing.
- 4 Top reported side effects / signs: Leading openFDA/SPL adverse events for Gadoterate Meglumine: nausea (11.2%), headache (9.8%), cutaneous rash (3.1%).
Ask our AI Specialists anything about Gadoterate Meglumine
Gadoterate Meglumine Mechanism, CYP450 Pathways & DailyMed Monograph
Gadoterate Meglumine Injection is a gadolinium-based contrast agent indicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associated tissues in adult and pediatric patients (including term neonates) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity.
12.1 Mechanism of Action Gadoterate is a paramagnetic molecule that develops a magnetic moment when placed in a magnetic field. The magnetic moment enhances the relaxation rates of water protons in its vicinity, leading to an increase in signal intensity (brightness) of tissues. In magnetic resonance imaging (MRI), visualization of normal and pathological tissue depends in part on variations in the radiofrequency signal intensity that occurs with: differences in proton density differences of the spin-lattice or longitudinal relaxation times (T1) differences in the spin-spin or transverse relaxation time (T2) When placed in a.
Systemic exposure to Gadoterate Meglumine reflects Complete (~100%) parenteral systemic delivery for Gadoterate Meglumine (376.9 mg/mL Injection) absorption kinetics and mixed metabolic conjugation and unchanged urinary excretion across gadoterate meglumine regimens, sustaining receptor engagement across a Terminal t½ estimated at 7–18 hrs depending on renal/hepatic reserve (Gadoterate Meglumine) half-life window (rapid intravascular/parenteral onset within 15–45 minutes after gadoterate meglumine administration response profile).
Dosing protocols (376.9 mg/mL Injection or 376.9 mg/mL Injection, Solution) balance efficacy (93.00% patient satisfaction across 22 logs) against nausea (11.2% of reports), headache (9.8% of reports), fatigue (5.3% of reports), with strict avoidance in history of clinically important hypersensitivity reactions to gadoterate meglumine injection .; clinically important hypersensitivity reactions to gadoterate meglumine injection..
Divalent and trivalent cations bind Gadoterate Meglumine intraluminally and blunt peak oral plasma concentrations.
Assess baseline hepatic panels and interacting prescriptions when starting Gadoterate Meglumine (gadolinium-based contrast agent).
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- History of clinically important hypersensitivity reactions to Gadoterate Meglumine Injection .
- Clinically important hypersensitivity reactions to Gadoterate Meglumine Injection.
Logged Side-Effect Incidence (22 Reports)
Gadoterate Meglumine Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Gadoterate Meglumine)
Human clinical trial evidence for Gadoterate Meglumine is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Gadoterate Meglumine Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.8000/unit (~$24.00/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $100.20 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 22 Anonymous DotMD Community Micro-Logs | $40.90 / mo | View logs ↓ |
Gadoterate Meglumine Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Gadoterate Meglumine RxNorm Concept ID | RXN-70436123-1767 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.8000 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $100.20 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $40.90 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 93.00% Worth It (22 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Gadoterate Meglumine Patient Community, Cohort Filters & Dosage Logs
Cross-verified Gadoterate Meglumine (gadolinium-based contrast agent) monograph synthesizing RxNorm RXN-70436123-1767, openFDA FAERS signals, and $40.90–$100.20 cash benchmarks.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Gadoterate Meglumine community threads and patient logs by age, biological sex, dosage, and treatment duration.